Chart Events
Performance Outlook
| Previous Close | 1.9600 |
| Open | 2.0700 |
| Bid | 2.0700 x 3000 |
| Ask | 2.1100 x 900 |
| Day's Range | 1.9600 - 2.1100 |
| 52 Week Range | 1.7700 - 5.0400 |
| Volume | |
| Avg. Volume | 145,715 |
| Market Cap | 96.144M |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.10 |
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/28/202355,583,76861,651,088 About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunothe
- GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to
- GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 product candidate fully manufactured in-house Encouraging preliminary results from Phase 1 AMELI-01 study
